Description: REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Home Page: www.regenxbio.com
RGNX Technical Analysis
9804 Medical Center Drive
Rockville,
MD
20850
United States
Phone:
240 552 8181
Officers
Name | Title |
---|---|
Mr. Kenneth T. Mills | Pres, CEO & Director |
Mr. Vittal K. Vasista | Exec. VP & Chief Financial Officer |
Mr. Curran M. Simpson M.S. | Exec. VP and Chief Operations & Technology Officer |
Dr. Olivier Danos Ph.D. | Exec. VP & Chief Scientific Officer |
Mr. Patrick J. Christmas II, J.D. | Exec. VP & Chief Legal Officer |
Ms. Tricia Truehart | VP of Investor Relations & Corp. Communications |
Mr. Andrew Yost | VP of Corp. Devel. |
Ms. Shiva G. Fritsch | Chief People Officer |
Dr. Laura A. Coruzzi J.D., Ph.D. | Sr. VP of Intellectual Property |
Dr. Ram Palanki Pharm.D. | Sr. VP of Commercial Strategy & Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 13.2857 |
Price-to-Book MRQ: | 1.8252 |
Price-to-Sales TTM: | 2.0631 |
IPO Date: | 2015-09-17 |
Fiscal Year End: | December |
Full Time Employees: | 372 |